Mark J. Ratain to Protein Kinases
This is a "connection" page, showing publications Mark J. Ratain has written about Protein Kinases.
Connection Strength
0.590
-
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.
Score: 0.298
-
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 2005 Jan 01; 65(1):46-53.
Score: 0.224
-
Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007 Oct; 82(4):381-8.
Score: 0.067